Company: AIP
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001667011-25-000022
Chunk: 254

Company: Arteris, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 254
---
2016 Plan will be available for issuance under the 2021 Plan.Stock OptionsThe following table summarizes the stock option activities under the Company’s 2016 and 2021 Plan:Options OutstandingNumber of SharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value ($'000s)BALANCE—December 31, 20242,197,604 $2.27 5.48$17,404 Granted280,000 $9.28 Exercised(145,959)$1.01 Canceled— $— BALANCE—March 31, 20252,331,645 $3.19 4.87$9,910 Options vested and exercisable—March 31, 20251,781,766 $1.70 3.50$9,780 The aggregate intrinsic value of the options exercised for the three months ended March 31, 2025 and 2024 was $1.3 million and $1.4 million, respectively. The total grant-date fair value of options vested was $0.1 million for both the three months ended March 31, 2025 and 2024.As of March 31, 2025, there was $2.3 million of unamortized stock-based compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 3.4 years.The fair value of each stock option granted is estimated using the Black-Scholes option-pricing model, which uses (i) a risk-free interest rate based on the U.S. Treasury zero coupon issues for an equivalent expected term of options; (ii) expected term based on the simplified method; (iii) volatility based on historical volatilities of the Company’s common stock and that of several peer companies, as the Company does not have sufficient trading history for its common stock; and (iv) an expected dividend yield of zero as the Company has never declared or paid any cash dividend and does not currently plan to pay a cash dividend in the foreseeable future. Restricted Stock Units and AwardsThe Company granted 440,166 restricted stock units during the three months ended March 31, 2025. As of March 31, 2025, there was $30.9 million of unamortized stock-based compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average